What is Telesis Bio?
Telesis Bio operates at the intersection of biotechnology and advanced manufacturing, providing the essential tools required for the rapid design and creation of synthetic DNA. As the creator of the BioXp system—the industry's only synthetic biology workstation—and the developer of the Gibson Assembly method, the company serves as a foundational partner for researchers in biologics drug discovery and gene therapy. Its market position is defined by its ability to streamline complex laboratory processes, effectively reducing the time-to-market for critical therapeutic innovations. By offering comprehensive, end-to-end solutions, Telesis Bio empowers organizations to overcome traditional bottlenecks in genome editing and cell therapy development.
How much funding has Telesis Bio raised?
Telesis Bio has raised a total of $28M across 1 funding round:
Other Financing Round
$28M
Other Financing Round (2023): $28M with participation from Novalis LifeSciences, Northpond Ventures, and BroadOak Capital Partners
Key Investors in Telesis Bio
Novalis LifeSciences
A boutique investment and advisory firm specializing in venture capital and private equity for life science tools, diagnostics, and biopharma therapeutics.
Northpond Ventures
A venture capital firm dedicated to advancing science and technology by supporting breakthrough innovations and entrepreneurial ventures with significant human impact.
BroadOak Capital Partners
A boutique financial institution providing growth capital and advisory services specifically tailored to the life sciences and biopharma services sectors.
What's next for Telesis Bio?
Looking ahead, the strategic deployment of this capital will likely focus on deepening the company's penetration into the global biopharma market. With the backing of specialized life science investors, Telesis Bio is expected to prioritize the expansion of its automated workstation capabilities and the refinement of its synthetic biology software suite. The company's roadmap suggests a continued emphasis on scaling its operational infrastructure to meet the increasing demand for personalized medicine and rapid vaccine production. As the industry shifts toward more modular and automated research environments, Telesis Bio is poised to remain a central player in the evolution of synthetic biology, driving both technical innovation and commercial growth in the coming fiscal periods.
See full Telesis Bio company page
